Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott M Wasserman

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Physiological Genomics|November 7, 2002
Gene expression profile of human endothelial cells exposed to sustained fluid shear stressScott M Wasserman, Fuad Mehraban, Laszlo G Komuves, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Clinical Pharmacology in Drug Development|January 25, 2019
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and SafetyEdward Lee, John P Gibbs, Maurice G Emery, et al.
Journal of the American College of Cardiology|October 29, 2013
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)Nihar R Desai, Robert P Giugliano, Jing Zhou, et al.
European Journal of Heart Failure|October 10, 2009
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failureMarc Klapholz, William T Abraham, Jalal K Ghali, et al.
Journal of Clinical Pharmacology|November 19, 2016
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)John P Gibbs, Sameer Doshi, Mita Kuchimanchi, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Physiological Genomics|November 7, 2002
Gene expression profile of human endothelial cells exposed to sustained fluid shear stressScott M Wasserman, Fuad Mehraban, Laszlo G Komuves, et al.
Circulation|December 13, 2016
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein MetabolismGerald F Watts, Dick C Chan, Ricardo Dent, et al.
Lancet (London, England)|October 6, 2014
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trialFrederick J Raal, Narimon Honarpour, Dirk J Blom, et al.
Cardiovascular Drugs and Therapy|March 4, 2016
Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 StudyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|January 31, 2014
Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapyLeslie Cho, Michael Rocco, David Colquhoun, et al.
Clinical Cardiology|August 19, 2018
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studiesErik Stroes, Jennifer G Robinson, Frederick J Raal, et al.
Clinical Pharmacology in Drug Development|January 25, 2019
Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and SafetyEdward Lee, John P Gibbs, Maurice G Emery, et al.
Journal of the American College of Cardiology|October 29, 2013
AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57)Nihar R Desai, Robert P Giugliano, Jing Zhou, et al.
European Journal of Heart Failure|October 10, 2009
The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failureMarc Klapholz, William T Abraham, Jalal K Ghali, et al.
Journal of Clinical Pharmacology|November 19, 2016
Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)John P Gibbs, Sameer Doshi, Mita Kuchimanchi, et al.
Pageof 10